Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (158 reviews)

For research use only. Not for use in humans.

Catalog No.S1001

158 publications

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 158 publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )
Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )
Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )
Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )
Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )
J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )
Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M362[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MomzTWM2OD1yLkCwOlY6KM7:TR?=	MYDTRW5ITVJ?
MV-4-11	M2HzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEG1PFYh\|ryP	M4PPc3NCVkeHUh?=
NKM-1	NXfxbpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf2b3p[UUN3ME2wMlAyPjl7IN88US=>	MX\TRW5ITVJ?
ML-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7YT\|BQUUN3ME2wMlAyQTh\|IN88US=>	NVzyfFB1W0GQR1XS
BV-173	NIrnV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf6TWM2OD1yLkCyN\|E1KM7:TR?=	NXrK[HFoW0GQR1XS
RS4-11	M1PRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\i[GlEPTB;MD6wNlU5PyEQvF2=	NGTzeZdUSU6JRWK=
HL-60	NXn5OZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMEK5NFgh\|ryP	M{DTfXNCVkeHUh?=
KY821	NYDGUY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEK5O\|Uh\|ryP	NUjyPJhKW0GQR1XS
ECC10	NFzhVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon0TWM2OD1yLkCzO\|kzKM7:TR?=	M{HCNXNCVkeHUh?=
NCI-H720	NYLFU5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDyR2xbUUN3ME2wMlA1ODFzIN88US=>	M4fV[HNCVkeHUh?=
QIMR-WIL	NFLFSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TkPGlEPTB;MD6wOFI5PyEQvF2=	NYr1bZk6W0GQR1XS
KG-1	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF6yd\|FKSzVyPUCuNFQ1QDZizszN	Mnv6V2FPT0WU
TGW	NEfqXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjHb2JKSzVyPUCuNFQ3OzNizszN	NXTyWmtLW0GQR1XS
ATN-1	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DoTGlEPTB;MD6wOFc{OyEQvF2=	Ml71V2FPT0WU
RH-18	M1HwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PGc2lEPTB;MD6wOlA1QCEQvF2=	MVXTRW5ITVJ?
EW-18	M3nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjwWJd7UUN3ME2wMlA3QDRzIN88US=>	MomxV2FPT0WU
NB17	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\EV2pZUUN3ME2wMlA4OTJ2IN88US=>	MYLTRW5ITVJ?
SK-NEP-1	NYjXVph[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrxTHhKSzVyPUCuNFczOTNizszN	MX7TRW5ITVJ?
P12-ICHIKAWA	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC1cVFKSzVyPUCuNFc4PzhizszN	MUXTRW5ITVJ?
KARPAS-45	M{jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljhTWM2OD1yLkC3PFE2KM7:TR?=	MWHTRW5ITVJ?
EW-3	M1rjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXzdWdKSzVyPUCuNFgxPTNizszN	MXzTRW5ITVJ?
NB13	NVvwbI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPrbXdKSzVyPUCuNFgzODNizszN	NHjndY5USU6JRWK=
NCI-H209	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnkb2ZKSzVyPUCuNFg4ODRizszN	MknqV2FPT0WU
NCI-H1092	NYPs[29RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PUR2lEPTB;MD6xNFI4PSEQvF2=	M3PXenNCVkeHUh?=
NH-12	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMUC3OFQh\|ryP	M3P3RnNCVkeHUh?=
697	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\0eGlEPTB;MD6xNFg{QSEQvF2=	NFTWeHlUSU6JRWK=
KE-37	M4fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXLclRKSzVyPUCuNVE{PyEQvF2=	NVHHTGtMW0GQR1XS
MOLT-4	NVrRVWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMUWxOlkh\|ryP	NUP2[HdbW0GQR1XS
CHP-134	NV7CcIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMU[zNFYh\|ryP	MWjTRW5ITVJ?
D-283MED	NEOwdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrhc2pNUUN3ME2wMlE4Pjh4IN88US=>	NXvBUYI3W0GQR1XS
LU-135	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDmVYlKSzVyPUCuNVg2PTJizszN	MWXTRW5ITVJ?
LU-134-A	NHnVUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7tfW1KSzVyPUCuNVg3PzFizszN	NYnSWJJEW0GQR1XS
EM-2	NF[3TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jEb2lEPTB;MD6xPVkyQCEQvF2=	MX7TRW5ITVJ?
LU-139	NXjkUWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGO3Xo5KSzVyPUCuNlA1QThizszN	Ml\qV2FPT0WU
ALL-PO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjVTWM2OD1yLkKxPVg5KM7:TR?=	M3TydnNCVkeHUh?=
NB12	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzsW4M4UUN3ME2wMlI{OTF3IN88US=>	MYHTRW5ITVJ?
KP-N-YN	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fOTGlEPTB;MD6yN\|U4OyEQvF2=	M2TLPHNCVkeHUh?=
BEN	NFHI[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrsfW5KSzVyPUCuNlM6PjhizszN	NGHBdI5USU6JRWK=
HCC1569	M2TjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHMUY5KSzVyPUCuNlUyODZizszN	NXHLZ3lvW0GQR1XS
HuO9	NEDFTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfFfmZKSzVyPUCuNlY4OTVizszN	M1vRNXNCVkeHUh?=
WM-115	NV\FVHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojqTWM2OD1yLkK3O\|M5KM7:TR?=	M{\TTXNCVkeHUh?=
CCRF-CEM	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwM{O1Nlkh\|ryP	MoG0V2FPT0WU
IST-SL1	NEXrW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nCemlEPTB;MD6zOVM1OyEQvF2=	NWLic\|loW0GQR1XS
BE-13	NXjwNVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17VU2lEPTB;MD6zOlQ2QSEQvF2=	MV3TRW5ITVJ?
COR-L88	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDHTWM2OD1yLkO2OVQh\|ryP	MYHTRW5ITVJ?
DOHH-2	NYHjVZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoixTWM2OD1yLkSxNFI{KM7:TR?=	MkftV2FPT0WU
A704	M{e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\Pc3dKSzVyPUCuOFI3PyEQvF2=	M2rRPXNCVkeHUh?=
KNS-81-FD	NUnLb4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwNESwNVch\|ryP	M1;YRnNCVkeHUh?=
RPMI-8226	NXWwNlJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwNEW2OVIh\|ryP	Mn74V2FPT0WU
TGBC24TKB	NYW1N5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXvUoZKSzVyPUCuOFU4PzhizszN	M{LwV3NCVkeHUh?=
NCI-H1304	NX72WmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHsTWM2OD1yLkS2NVU4KM7:TR?=	M2e3S3NCVkeHUh?=
MOLT-13	NUHpR2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PKXWlEPTB;MD60OlYyOyEQvF2=	M37LR3NCVkeHUh?=
EW-22	M2nJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwNE[2O\|Eh\|ryP	NWrUWIp[W0GQR1XS
MS-1	NGK4[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXFWXZKSzVyPUCuOFY6OzNizszN	NWr0SVg3W0GQR1XS
RMG-I	M2HSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrtUZppUUN3ME2wMlQ6PDZ2IN88US=>	M{nyO3NCVkeHUh?=
NTERA-S-cl-D1	NWnuVINkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjPXYVRUUN3ME2wMlUxODF7IN88US=>	NFTYWXZUSU6JRWK=
NCI-H1048	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{GweGlEPTB;MD61NFk2OyEQvF2=	NU[xfoZ5W0GQR1XS
SW1417	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGm2bYlKSzVyPUCuOVU1OzhizszN	NFz6OpRUSU6JRWK=
DB	NFjXd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4C4RWlEPTB;MD61O\|A5KM7:TR?=	M3WzVnNCVkeHUh?=
MEG-01	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwNUizNkDPxE1?	NEHYc\|JUSU6JRWK=
EW-13	M4e2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwNUizOFEh\|ryP	MkOwV2FPT0WU
LAMA-84	NGPucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\nTWM2OD1yLkW5NlA4KM7:TR?=	NFv0[5ZUSU6JRWK=
J-RT3-T3-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjXPXBKSzVyPUCuOlA5ODhizszN	M1XXbHNCVkeHUh?=
MOLT-16	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3naRmlEPTB;MD62OVI3PCEQvF2=	NI\zbXVUSU6JRWK=
DU-4475	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn4TWM2OD1yLk[1OFI4KM7:TR?=	NX[xNll[W0GQR1XS
HAL-01	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\1OmlEPTB;MD63NlU1QSEQvF2=	NHPiOWlUSU6JRWK=
RD	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwN{W4PVkh\|ryP	MlG5V2FPT0WU
OAW-28	NUPTe5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwN{izO{DPxE1?	NYj6VWxUW0GQR1XS
HCC38	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXMTWM2OD1yLkiwNVkh\|ryP	M1jufHNCVkeHUh?=
NMC-G1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PnZmlEPTB;MD64NVEzOSEQvF2=	MoHhV2FPT0WU
EW-16	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm1fY51UUN3ME2wMlgyOzJ6IN88US=>	MlnGV2FPT0WU
DU-145	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXwdJZKSzVyPUCuPFk6OjNizszN	MYfTRW5ITVJ?
HPAF-II	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwOUK2Nlgh\|ryP	MlXVV2FPT0WU
A427	M{f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwOUOwNlIh\|ryP	MWLTRW5ITVJ?
PA-1	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXkTIdmUUN3ME2wMlk2PjR{IN88US=>	M4fIVnNCVkeHUh?=
OAW-42	NGr6[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwOU[xOFYh\|ryP	NXnReJE4W0GQR1XS
L-428	NFr3eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTFwMEGyOUDPxE1?	NEHaR2NUSU6JRWK=
COLO-824	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf4VFdKSzVyPUGuNFE4ODhizszN	MVPTRW5ITVJ?
P30-OHK	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHWfZl3UUN3ME2xMlA1Pjh6IN88US=>	MlrJV2FPT0WU
NCI-H2170	NH3HS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn2PXNKSzVyPUGuNFYzOyEQvF2=	Ml23V2FPT0WU
HCC2998	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\oXGpKSzVyPUGuNFcyOzVizszN	Ml3HV2FPT0WU
NB14	NUHPT4FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj2UVNKSzVyPUGuNVM4PDhizszN	M1;6WnNCVkeHUh?=
TGBC1TKB	M1P5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XhNWlEPTB;MT6xOFE2OiEQvF2=	M1PlRXNCVkeHUh?=
KP-N-YS	NY\uR2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInwPVFKSzVyPUGuNVYzOzZizszN	NVThV2QxW0GQR1XS
CAL-120	M3XqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPWZoNJUUN3ME2xMlE3PDJ7IN88US=>	MnXkV2FPT0WU
SBC-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknMTWM2OD1zLkG5NFU{KM7:TR?=	MX3TRW5ITVJ?
C32	NUfue452T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnn[YtKSzVyPUGuNVkxQDhizszN	NIXvTmhUSU6JRWK=
HCC2157	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LwV2lEPTB;MT6xPVQ6PCEQvF2=	Ml75V2FPT0WU
COLO-792	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q0TWlEPTB;MT6yNFA4OSEQvF2=	NHrTTVZUSU6JRWK=
ES7	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHnTWM2OD1zLkK3PVUyKM7:TR?=	M4LyXHNCVkeHUh?=
HEL	M4jSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL4TWM2OD1zLkOxNFI6KM7:TR?=	M4jvT3NCVkeHUh?=
ES4	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwM{S5PVgh\|ryP	M{PTeHNCVkeHUh?=
NCI-SNU-1	NIW5TYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTFwM{[1OVUh\|ryP	M2q4VHNCVkeHUh?=
MDA-MB-415	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HTcWlEPTB;MT6zPFg2KM7:TR?=	M1LzN3NCVkeHUh?=
NCI-H2342	NWHXV3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFwNECyOlkh\|ryP	M3zBVXNCVkeHUh?=
NB69	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG0b4NYUUN3ME2xMlQ3OjdzIN88US=>	M{jVcHNCVkeHUh?=
D-247MG	M4ntV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIm1fndKSzVyPUGuOVEyOjJizszN	NW\vWoZpW0GQR1XS
SCC-4	NUWzSXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDHTWM2OD1zLkW5PFg4KM7:TR?=	NIXIN4ZUSU6JRWK=
HuH-7	NYjtOFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTFwNkeyPVMh\|ryP	NFTt[4VUSU6JRWK=
A388	NVfVbHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfXOIhKSzVyPUGuOlg4OjRizszN	MYLTRW5ITVJ?
Calu-3	NX;Oe3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jJdGlEPTB;MT63NFY6PyEQvF2=	NUGzTIM5W0GQR1XS
NCI-H1648	NELWW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELUVYtKSzVyPUGuO\|E1OThizszN	NVzNS4ZTW0GQR1XS
NCI-H2052	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK5V2FKSzVyPUGuO\|IzODFizszN	M4DiZ3NCVkeHUh?=
Ramos-2G6-4C10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LDWmlEPTB;MT63N\|Y2PiEQvF2=	M2HpPHNCVkeHUh?=
DEL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H5emlEPTB;MT63OFY6OiEQvF2=	NHmwdmlUSU6JRWK=
SNU-423	NID3clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFwN{ixOVch\|ryP	MmLnV2FPT0WU
COR-L23	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\nTWM2OD1zLke5PFc1KM7:TR?=	MnW0V2FPT0WU
OMC-1	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTFwOE[wNVYh\|ryP	NXnR[2hSW0GQR1XS
EW-11	M{\wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjafXpKSzVyPUGuPVU3PTdizszN	M1rkNHNCVkeHUh?=
HSC-3	NHzKbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFT6T5BKSzVyPUGuPVY{PjVizszN	NHXwVI1USU6JRWK=
MLMA	M3vRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnNNFJoUUN3ME2xMlk3Pjd5IN88US=>	NEHPOZlUSU6JRWK=
RCM-1	M1;J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3zTWM2OD1{LkCwN\|k6KM7:TR?=	M3eySnNCVkeHUh?=
MFE-280	NHPaXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfoTmJYUUN3ME2yMlAzQDR6IN88US=>	MYDTRW5ITVJ?
ES8	NIrNZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnTTWM2OD1{LkK1OFcyKM7:TR?=	Ml34V2FPT0WU
TE-11	NFHZemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPrTItKSzVyPUKuNlk1PzNizszN	NGrRdmdUSU6JRWK=
HuO-3N1	NVrTTFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[0[mlEPTB;Mj60PFc5KM7:TR?=	MVjTRW5ITVJ?
MHH-NB-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jlfGlEPTB;Mj61NVE2QCEQvF2=	NEPLXYtUSU6JRWK=
TGBC11TKB	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTJwNUe2PFEh\|ryP	M2fq[XNCVkeHUh?=
HOP-92	M{Dld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXKTWM2OD1{LkW4O\|Q{KM7:TR?=	M4SzPHNCVkeHUh?=
IGR-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvKTWM2OD1{Lk[yNFM2KM7:TR?=	MlvHV2FPT0WU
GOTO	NEfiT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJwNkWzO\|ch\|ryP	NE\Id5hUSU6JRWK=
NCI-H1650	NGGySpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWq0NYhjUUN3ME2yMlczOjF3IN88US=>	NF;ROolUSU6JRWK=
NCI-H1581	NGG5R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPwZ4tWUUN3ME2yMlc6PjhzIN88US=>	NFzCZ2dUSU6JRWK=
NCI-H2405	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDmNlB7UUN3ME2yMlgzPzh{IN88US=>	MV\TRW5ITVJ?
U-118-MG	NVn3RpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJwOU[0PVEh\|ryP	Mmq4V2FPT0WU
DoTc2-4510	M{XTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDmenJMUUN3ME2zMlAyPDF5IN88US=>	M1HvVnNCVkeHUh?=
NCI-H596	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LVeGlEPTB;Mz6wOFk6PyEQvF2=	M3TpcXNCVkeHUh?=
MPP-89	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jx[mlEPTB;Mz6wOVY3PiEQvF2=	M1nMeHNCVkeHUh?=
GCIY	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTNwMkC0PVEh\|ryP	NYXtUGNXW0GQR1XS
SW626	M2\MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTNwMkS1OFMh\|ryP	M37BdHNCVkeHUh?=
OCI-AML2	M4rH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LEbGlEPTB;Mz6zNVI4OiEQvF2=	M3rSeXNCVkeHUh?=
NBsusSR	NV3lfoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXuTWM2OD1\|LkO0PVM5KM7:TR?=	MnLoV2FPT0WU
AN3-CA	M1[xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTNwNESyN\|gh\|ryP	NIHtdotUSU6JRWK=
EFM-19	M373fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\TRVIzUUN3ME2zMlQ5OzN7IN88US=>	Mk[4V2FPT0WU
RVH-421	NHmxco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTrVpA2UUN3ME2zMlU3QDd5IN88US=>	M4nzcnNCVkeHUh?=
5637	NGD1SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\HdmlEPTB;Mz62NVExOyEQvF2=	M3rFcXNCVkeHUh?=
PANC-08-13	NVPneIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjDXm1KSzVyPUOuOlM1PzJizszN	NH\aT\|VUSU6JRWK=
H9	M3LmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPoPIZKSzVyPUOuOlcyPDRizszN	MoTqV2FPT0WU
KARPAS-299	NVvp[IJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnYTWM2OD1\|Lk[3N\|YyKM7:TR?=	NVzlfWNoW0GQR1XS
TE-5	NH7OfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXSx[ZlmUUN3ME2zMlcxPzB7IN88US=>	NYiyPIdqW0GQR1XS
NOS-1	NWraWXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TjNWlEPTB;Mz63PVg{PCEQvF2=	MUnTRW5ITVJ?
HH	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDsVppKSzVyPUOuPFM5PjhizszN	NHvSc5RUSU6JRWK=
769-P	M1H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXrPG5KSzVyPUOuPFk2OSEQvF2=	MkPNV2FPT0WU
CHP-212	NVXzcpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle1TWM2OD1\|LkmyOVQ6KM7:TR?=	NWfBbYxuW0GQR1XS
NCI-H82	NGW4NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTNwOUW5N\|Yh\|ryP	NV\pSnllW0GQR1XS
Mo-T	NUHkW2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTzTWM2OD12LkC0N\|EzKM7:TR?=	MmPZV2FPT0WU
BB65-RCC	M4\YOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFK2fYtKSzVyPUSuNFQ{QTlizszN	NGXuNW9USU6JRWK=
SW1990	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrCVmdKSzVyPUSuNFU6ODhizszN	NEPWTGtUSU6JRWK=
LK-2	NULWb\|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;BfGlEPTB;ND6xNVI6OyEQvF2=	M3T2TXNCVkeHUh?=
ES5	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF32OopKSzVyPUSuNVM6QDVizszN	MUfTRW5ITVJ?
JVM-3	NHP2U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTRwMUiyNlIh\|ryP	NUnrN4pMW0GQR1XS
RPMI-7951	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTRwMkK0NVMh\|ryP	Mo\OV2FPT0WU
Calu-6	M4LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTRwMke4PFEh\|ryP	MYXTRW5ITVJ?
LC-2-ad	M3jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnHWnd{UUN3ME20MlI6PTZ6IN88US=>	NGPqNJJUSU6JRWK=
SW954	M4Pacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTRwMkm2OkDPxE1?	M2CyO3NCVkeHUh?=
H-EMC-SS	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TGNmlEPTB;ND6zNVg{OSEQvF2=	M2q3N3NCVkeHUh?=
ES3	M4T3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfzTWM2OD12LkO1OFQyKM7:TR?=	NGXnbGZUSU6JRWK=
no-11	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTRwM{W1OVQh\|ryP	NV7ue2x2W0GQR1XS
LAN-6	M{KzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXpTWM2OD12LkS1NVg6KM7:TR?=	MnTsV2FPT0WU
FTC-133	NHzpUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF25SnJKSzVyPUSuOVM6PSEQvF2=	MmjKV2FPT0WU
8505C	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTRwNUSyN{DPxE1?	MYrTRW5ITVJ?
SW620	M4rqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjwVplJUUN3ME20MlU4ODV5IN88US=>	M3HsUnNCVkeHUh?=
BCPAP	NHPE[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;TTHJKSzVyPUSuOlM1QDFizszN	NVTVR\|A{W0GQR1XS
SK-LU-1	NUDxdFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXVXIZlUUN3ME20MlY3ODh7IN88US=>	MmDMV2FPT0WU
NCI-H1623	NFPDSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPEeFJKSzVyPUSuO\|AzOjhizszN	M4H4XnNCVkeHUh?=
C2BBe1	NFvQfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn4eolKSzVyPUSuO\|QxODhizszN	NYrZVYlXW0GQR1XS
GP5d	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLrOZNyUUN3ME20Mlc5Ozh6IN88US=>	Ml22V2FPT0WU
NB6	NYCxeml3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTRwOE[yNFQh\|ryP	NEPzd4RUSU6JRWK=
MDA-MB-157	NUX5ZXNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTRwOEi3OkDPxE1?	MlW5V2FPT0WU
UMC-11	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTRwOEi5OlQh\|ryP	NYXtNGVIW0GQR1XS
HCC1419	M4nNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTRwOUCwOlMh\|ryP	MVzTRW5ITVJ?
NCI-H2029	NFvvT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f5eWlEPTB;ND65OFE5PSEQvF2=	M1XzdHNCVkeHUh?=
LXF-289	NFXhTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHSWW9KSzVyPUWuNFM4OTlizszN	NFrrfmJUSU6JRWK=
KINGS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTVwMEe3OFQh\|ryP	NWr1TFFvW0GQR1XS
HD-MY-Z	M37QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XCeWlEPTB;NT6yN\|k3QSEQvF2=	M3jkZnNCVkeHUh?=
ESS-1	NVnaZW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvuVXM6UUN3ME21MlI2PTl5IN88US=>	MofyV2FPT0WU
GI-1	NELJbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTVwMke5NlYh\|ryP	MWfTRW5ITVJ?
RPMI-2650	NEDKSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\RTWM2OD13LkO2NVYh\|ryP	MlfUV2FPT0WU
IA-LM	NGfTeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\Ke2tKSzVyPUWuN\|k5PzFizszN	MWDTRW5ITVJ?
KP-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDzTWM2OD13LkS2N\|M1KM7:TR?=	NITMd21USU6JRWK=
G-402	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwNUG4OlUh\|ryP	NWf1UVd{W0GQR1XS
OS-RC-2	NEDEVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK4[lZKSzVyPUWuOVI3ODRizszN	M4XEUnNCVkeHUh?=
NCI-H1155	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPHT5ltUUN3ME21MlU1QTV3IN88US=>	M3X4bHNCVkeHUh?=
OE19	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK3fJVZUUN3ME21MlY5PjJ2IN88US=>	M{HYNXNCVkeHUh?=
U-2-OS	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPxS\|NWUUN3ME21Mlg6ODF\|IN88US=>	MVXTRW5ITVJ?
SCC-15	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f6O2lEPTB;NT65N\|Y3OiEQvF2=	MXXTRW5ITVJ?
NCI-H630	NFvWNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\Sc4FKSzVyPUWuPVk1ODRizszN	MWLTRW5ITVJ?
PFSK-1	NUXEdoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPEZ4M4UUN3ME22MlA2OjV7IN88US=>	M1:yUXNCVkeHUh?=
NCI-H1770	NVmxT2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTIb4NmUUN3ME22MlIxQDd2IN88US=>	NEj4fZBUSU6JRWK=
SK-MEL-3	NEDVO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTZwNEK5NVUh\|ryP	NV\WPJJQW0GQR1XS
LB1047-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfTTWM2OD14LkS3OlI2KM7:TR?=	M1u5fXNCVkeHUh?=
NCI-H446	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfiNo5rUUN3ME22MlYzQTJ3IN88US=>	MnP4V2FPT0WU
SW780	M2TVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTZwN{CxPFUh\|ryP	NV2xNphYW0GQR1XS
NEC8	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHTfYxKSzVyPU[uO\|Y3OyEQvF2=	MknqV2FPT0WU
NOMO-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHM[ZdKSzVyPU[uO\|gyOTFizszN	NFHPdlBUSU6JRWK=
COLO-668	NFHOUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxS4hFUUN3ME22Mlg1Ozh5IN88US=>	M132WHNCVkeHUh?=
MC116	M4fobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfDTWM2OD14LkmzPFk4KM7:TR?=	MmexV2FPT0WU
HCC1937	MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fvOGlEPTB;Nj65PVI2OSEQvF2=	M1K5[HNCVkeHUh?=
NCI-N87	NGSxR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHDZ\|FKSzVyPUeuNVkzQTNizszN	MX;TRW5ITVJ?
COLO-320-HSR	MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:5UFhKSzVyPUeuNlI4OzhizszN	NFrDeFdUSU6JRWK=
HCC1806	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTdwMk[wOFQh\|ryP	NWL3fm51W0GQR1XS
OVCAR-3	M{O1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13VPGlEPTB;Nz6zN\|A{QCEQvF2=	MXvTRW5ITVJ?
NUGC-3	NG\tWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTdwM{m2PVQh\|ryP	M2H0[HNCVkeHUh?=
SW1783	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj3fZJKSzVyPUeuOFMyPzVizszN	MlnGV2FPT0WU
GCT	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPu[FJKSzVyPUeuOVY6ODZizszN	NHHBd\|FUSU6JRWK=
NCI-H2126	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTdwN{O2NlUh\|ryP	NIDVb4ZUSU6JRWK=
MEL-HO	NFztTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHlTWM2OD15Lke3NFU1KM7:TR?=	MX3TRW5ITVJ?
CAPAN-1	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknpTWM2OD15Lke3N\|U4KM7:TR?=	NIToeVlUSU6JRWK=
SW756	M2rWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVGwVIdMUUN3ME23Mlc5OzN\|IN88US=>	M1L0SnNCVkeHUh?=
SKG-IIIa	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz1NVdKSzVyPUeuPFE5QTJizszN	NILn[5NUSU6JRWK=
HCE-T	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUO4eXAxUUN3ME23Mlg4Pzh\|IN88US=>	MULTRW5ITVJ?
Ca-Ski	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jGUWlEPTB;Nz65PVM5OyEQvF2=	NGixbllUSU6JRWK=
COLO-684	NE\BR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXq2NW5NUUN3ME24MlAyQDF6IN88US=>	NETNUo5USU6JRWK=
KYSE-70	M{\odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH22[3hKSzVyPUiuNFc4OjlizszN	M2\xdnNCVkeHUh?=
TI-73	M1qzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\IXG1KSzVyPUiuNlU5PTFizszN	NWq5NVZZW0GQR1XS
BT-20	NFe2d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPhRW1KSzVyPUiuNlYxPTJizszN	NIWweGdUSU6JRWK=
MHH-ES-1	M17BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjzOmJKSzVyPUiuOVE5OzRizszN	M33zWnNCVkeHUh?=
TE-12	M2T5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRThwNUm5N\|Eh\|ryP	MnjpV2FPT0WU
YH-13	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVSyfoZ2UUN3ME24MlYyODB6IN88US=>	NGnDZ4NUSU6JRWK=
SF126	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M332XGlEPTB;OD64N\|g3PSEQvF2=	MoHOV2FPT0WU
J82	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRThwOUCwN\|gh\|ryP	NVTTe3BvW0GQR1XS
RCC10RGB	NVe5bok6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fYSWlEPTB;OD65PVU3OSEQvF2=	NGOxNmFUSU6JRWK=
SK-UT-1	M2e0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTlwMES5OFUh\|ryP	Mmq5V2FPT0WU
LB2241-RCC	NEX2c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37JTGlEPTB;OT6xPVE{PyEQvF2=	MlvJV2FPT0WU
LB996-RCC	M3vYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTlwMUm4PUDPxE1?	NW\SZoNvW0GQR1XS
EPLC-272H	NY\aTG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnYNXlKSzVyPUmuN\|c3PTdizszN	NYf3[ZN3W0GQR1XS
CTV-1	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoX5TWM2OD17LkW2OVMzKM7:TR?=	MmjLV2FPT0WU
HSC-2	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjaTWM2OD17LkW3OVUh\|ryP	NEfWdpVUSU6JRWK=
SK-MEL-28	M{jQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXLTnBKSzVyPUmuOlE5QTNizszN	MXLTRW5ITVJ?
MMAC-SF	NGqzTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL1XGw3UUN3ME25MlY5PzVizszN	MXzTRW5ITVJ?
CP50-MEL-B	NVPibHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTlwN{W3PFIh\|ryP	MYDTRW5ITVJ?
HT-1080	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\xVmlEPTB;OT63O\|c{QSEQvF2=	Mo\KV2FPT0WU
HEC-1	NXT6bYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\hOHpKSzVyPUGwMlM{PTJizszN	MnLUV2FPT0WU
AGS	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4O1SGlEPTB;MUCuN\|c1KM7:TR?=	M1jSOHNCVkeHUh?=
GAMG	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jvWGlEPTB;MUCuOVE3OiEQvF2=	MlqwV2FPT0WU
SW48	M1:5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1ruNmlEPTB;MUCuOVE5QSEQvF2=	NXjJdIM{W0GQR1XS
U031	NWLBO2NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLyTWM2OD1zMD61PVA5KM7:TR?=	Mnv3V2FPT0WU
OVCAR-5	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\XSlVKSzVyPUGwMlY1OjlizszN	NYPzbHBxW0GQR1XS
SF295	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFyLk[3NFQh\|ryP	M2fWdnNCVkeHUh?=
BHT-101	M4XaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHCUJRKSzVyPUGwMlcyPzdizszN	M1PPVXNCVkeHUh?=
VMRC-RCZ	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoraTWM2OD1zMT6zNlAyKM7:TR?=	M1PSZXNCVkeHUh?=
ACHN	NFfFVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zPWmlEPTB;MUGuOFIyOSEQvF2=	NVfGRoU4W0GQR1XS
NCI-H526	M4T5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTFT\|ZKSzVyPUGxMlUxPDNizszN	NELIWXdUSU6JRWK=
MN-60	NV73[nloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;YTWM2OD1zMT61N\|kh\|ryP	MoPXV2FPT0WU
NCI-H2291	M2n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrIRZFKSzVyPUGxMlU1PjZizszN	NEDRc5dUSU6JRWK=
SCC-25	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HmW2lEPTB;MUGuO\|U2PiEQvF2=	MVnTRW5ITVJ?
SK-MEL-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTq[3BKSzVyPUGxMlc3OzdizszN	NWO4UHVjW0GQR1XS
SN12C	NWP5UoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H5[GlEPTB;MUGuPVM2PSEQvF2=	MnXUV2FPT0WU
NCI-H69	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G1ZmlEPTB;MUKuOFI{PCEQvF2=	NXnISZFMW0GQR1XS
ME-180	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTF{LkewOVQh\|ryP	MlHLV2FPT0WU
MC-IXC	M{DOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1G3[mlEPTB;MUKuO\|UyQCEQvF2=	M{PEXHNCVkeHUh?=
NCI-H2347	NULV[IU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfzW3JLUUN3ME2xNk44PjF2IN88US=>	NFr3[VlUSU6JRWK=
M059J	NEexNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTSem5wUUN3ME2xNk44PzJ5IN88US=>	NGXpdnVUSU6JRWK=
A2058	NFfZTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LNPWlEPTB;MUKuPFY5OSEQvF2=	M2TaUnNCVkeHUh?=
VA-ES-BJ	NF;IVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf1TpVKSzVyPUGyMlg4QDVizszN	MnTYV2FPT0WU
Ca9-22	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojETWM2OD1zMj65OFUyKM7:TR?=	NGf3UFBUSU6JRWK=
KNS-42	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXpTWM2OD1zMj65PVg1KM7:TR?=	MXvTRW5ITVJ?
LoVo	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV35W5BjUUN3ME2xN{4zOzF\|IN88US=>	M33jSHNCVkeHUh?=
AM-38	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX2eJNoUUN3ME2xN{4zPTZ4IN88US=>	M{X0VHNCVkeHUh?=
NB5	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7vTWM2OD1zMz6zO\|UzKM7:TR?=	MYDTRW5ITVJ?
L-363	NYDCZVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rKNmlEPTB;MUOuOFA{OyEQvF2=	NX3xXpdNW0GQR1XS
SK-MEL-30	M3TteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzDeZdKSzVyPUG0MlA3PDVizszN	NGTmbZdUSU6JRWK=
NCI-H1563	NFL5UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P3SWlEPTB;MUSuOlA{QSEQvF2=	M4jW[XNCVkeHUh?=
NCI-H2228	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHkNmpGUUN3ME2xOE43ODd5IN88US=>	MVTTRW5ITVJ?
MFM-223	NYHYTlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fET2lEPTB;MUWuNVgyOyEQvF2=	NG\wfVVUSU6JRWK=
LB831-BLC	NWLnR2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TmeGlEPTB;MUWuNlc3PyEQvF2=	NI\jfG5USU6JRWK=
SW872	NXXSfFI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnniTWM2OD1zNT6zNFg3KM7:TR?=	MWfTRW5ITVJ?
NCI-H522	NXvaXXltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXnTWM2OD1zNT6zN\|A3KM7:TR?=	NVfjPFV3W0GQR1XS
EW-1	M2POOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLmTWM2OD1zNT61OFYzKM7:TR?=	MlHVV2FPT0WU
HN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn2O\|ZKSzVyPUG1MlU6PDJizszN	MWnTRW5ITVJ?
SW837	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV22fIo{UUN3ME2xOU44QDR5IN88US=>	M2LwTHNCVkeHUh?=
SCC-9	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnHNGhMUUN3ME2xOU45OTF2IN88US=>	NFLY[WlUSU6JRWK=
MKN7	NU\FfmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPGW\|lsUUN3ME2xOU46PzN{IN88US=>	Mn;QV2FPT0WU
KYSE-410	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[3bnVmUUN3ME2xOk42QTFizszN	MkDmV2FPT0WU
SK-N-DZ	M4D3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LSU2lEPTB;MU[uOlEyPiEQvF2=	NFPhPWtUSU6JRWK=
COR-L105	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF4Lk[1Nlgh\|ryP	NEXKfnJUSU6JRWK=
LB2518-MEL	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF4LkizPFkh\|ryP	NF32dmFUSU6JRWK=
OVCAR-4	M2rXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH33bVdKSzVyPUG2Mlg5PjJizszN	NITkc5pUSU6JRWK=
TK10	NWfpd\|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTF4Lkm0O\|Mh\|ryP	NIXkS4xUSU6JRWK=
KNS-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f5R2lEPTB;MU[uPVc4PyEQvF2=	NGDBWZhUSU6JRWK=
RPMI-8866	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\WfGlEPTB;MUeuNVc{OiEQvF2=	NWjNfmd2W0GQR1XS
HuP-T4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGxTWM2OD1zNz6yOFk2KM7:TR?=	MYPTRW5ITVJ?
CGTH-W-1	NV30SpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTF5LkWyNVkh\|ryP	M1;uT3NCVkeHUh?=
T-24	NYXTO2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEG3eWhKSzVyPUG3MlU{PDdizszN	NVrDS4E4W0GQR1XS
HT-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Pne2lEPTB;MUeuOVkyPCEQvF2=	M4i3XXNCVkeHUh?=
KS-1	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjnV4tKSzVyPUG3MlY4OyEQvF2=	MmrKV2FPT0WU
NCI-H1792	M3mxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorZTWM2OD1zNz63PVgh\|ryP	NUPldJJ7W0GQR1XS
ABC-1	M{\J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fGfmlEPTB;MUeuPFE1OSEQvF2=	MXLTRW5ITVJ?
BPH-1	M3TnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF6LkG2PFUh\|ryP	NWXaSoFTW0GQR1XS
A431	NV;0RYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;Z[mlEPTB;MUiuOFEzPyEQvF2=	NG\QfWxUSU6JRWK=
T98G	M3fGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTF6LkWxOVch\|ryP	MWPTRW5ITVJ?
BHY	NH25ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTF6Lki2PUDPxE1?	NIjXTGZUSU6JRWK=
Capan-2	M{X5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1OzWGlEPTB;MUiuPVA4QCEQvF2=	NFfyZWpUSU6JRWK=
MDA-MB-175-VII	M1TPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnqxTWM2OD1zOD65NlA6KM7:TR?=	NWfaSZptW0GQR1XS
CAL-27	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF7LkC0PFch\|ryP	MWjTRW5ITVJ?
AsPC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP0d\|NKSzVyPUG5Mlg3PTdizszN	NH\5S3lUSU6JRWK=
KU812	M{L6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT3XZNpUUN3ME2xPU46PTd\|IN88US=>	NX2xeZVZW0GQR1XS
NCI-H441	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJyLkCwNUDPxE1?	M1fmSnNCVkeHUh?=
Mewo	M3HDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWS4OG1IUUN3ME2yNE4yOjh6IN88US=>	MXPTRW5ITVJ?
SK-MEL-24	NU\mVJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTJyLkG0O\|ch\|ryP	NYTOfIdpW0GQR1XS
NCI-H727	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfXTWM2OD1{MD6yO\|A1KM7:TR?=	MnLYV2FPT0WU
EKVX	NETsN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rBZWlEPTB;MkCuOlA3KM7:TR?=	NUPI[\|V7W0GQR1XS
RT-112	M{e5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHy4d3dKSzVyPUKwMlYyOjJizszN	MlnuV2FPT0WU
CAMA-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfIW\|cxUUN3ME2yNE46QDB\|IN88US=>	MmD1V2FPT0WU
SW900	M4HpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q5bWlEPTB;MkGuNFE1QSEQvF2=	MlXEV2FPT0WU
NCI-H23	NHW3[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n0TGlEPTB;MkGuNVI4PyEQvF2=	NXrFfpRyW0GQR1XS
SK-PN-DW	NXLOO4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojHTWM2OD1{MT6xOlQ6KM7:TR?=	NHG4cWtUSU6JRWK=
BB30-HNC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf3TWM2OD1{MT6yO\|Q2KM7:TR?=	M17lTHNCVkeHUh?=
VM-CUB-1	M3jXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDJVIlKSzVyPUKxMlM2OzZizszN	NY\VemJ7W0GQR1XS
IST-MEL1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTJzLkO2PVIh\|ryP	NY\xPZdxW0GQR1XS
CTB-1	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36ybGlEPTB;MkGuOFc2PSEQvF2=	NVXvWIVZW0GQR1XS
LCLC-103H	NXvz[WY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnjU3lyUUN3ME2yNk4yPTh{IN88US=>	MWLTRW5ITVJ?
PANC-03-27	M4Tyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTJ{LkWxOlkh\|ryP	NFnLc5RUSU6JRWK=
HTC-C3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\iNGlEPTB;MkKuOVU2PSEQvF2=	M1XvRnNCVkeHUh?=
TE-8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjuTWM2OD1{Mz6yOVY2KM7:TR?=	M2XxTHNCVkeHUh?=
NCI-H292	M1PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrRTWM2OD1{NT6zOVM3KM7:TR?=	NE\lcIlUSU6JRWK=
COLO-680N	M4\kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ3Lk[zNlkh\|ryP	MkDBV2FPT0WU
KYSE-520	M2qwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LqfWlEPTB;MkWuOlQ1KM7:TR?=	MXPTRW5ITVJ?
NB10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJ4LkOxNVch\|ryP	NE\iS\|RUSU6JRWK=
NCI-H661	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHlTWM2OD1{Nj60O\|E{KM7:TR?=	MUnTRW5ITVJ?
GMS-10	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPyTWM2OD1{Nj64OlM5KM7:TR?=	MVnTRW5ITVJ?
NCI-H2122	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jlUmlEPTB;Mk[uPVk6QCEQvF2=	MnexV2FPT0WU
OVCAR-8	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[5SWNlUUN3ME2yO{4xPjN6IN88US=>	MYfTRW5ITVJ?
DJM-1	M3;SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTJ5LkG0OVQh\|ryP	MVnTRW5ITVJ?
UACC-893	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHvRZNKSzVyPUK3Mlk5PzhizszN	NF36Z5lUSU6JRWK=
C8166	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LKRmlEPTB;MkiuOlk{QCEQvF2=	M1\1U3NCVkeHUh?=
NCI-H1693	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTJ6Lk[5O\|Uh\|ryP	Mo\NV2FPT0WU
TYK-nu	M3LpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTKOJhKSzVyPUOwMlA{PDVizszN	NFH6dGRUSU6JRWK=
SW1710	M{K4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNyLkGyOkDPxE1?	MYXTRW5ITVJ?
A375	NXP6RllbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjZdndKSzVyPUOwMlMzPDNizszN	NYXRcG5QW0GQR1XS
HMV-II	M3HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1L3PGlEPTB;M{GuN\|U6OiEQvF2=	NH\lR3ZUSU6JRWK=
NCI-H2087	M17YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrROIFKSzVyPUOxMlY{PTJizszN	M1HTSnNCVkeHUh?=
CAL-54	NYfFdZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTNzLkeyOFEh\|ryP	M4m5OXNCVkeHUh?=
HCC70	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Dy[WlEPTB;M{KuNVM5PyEQvF2=	MWPTRW5ITVJ?
ES1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTN{LkOwOlIh\|ryP	NHfENGFUSU6JRWK=
NCI-H1355	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XMdGlEPTB;M{OuNlA1KM7:TR?=	MXLTRW5ITVJ?
CFPAC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW2TWM2OD1\|Mz6yN\|MzKM7:TR?=	MnTTV2FPT0WU
MKN28	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1frSmlEPTB;M{OuN\|gxQSEQvF2=	NITHToVUSU6JRWK=
HDLM-2	M4L4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXWTWM2OD1\|Mz62PVMyKM7:TR?=	MV7TRW5ITVJ?
PANC-10-05	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXTTWM2OD1\|ND6xNFE1KM7:TR?=	MUTTRW5ITVJ?
SAS	M4nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLsfoFKSzVyPUO0MlQ2PjVizszN	MmPuV2FPT0WU
HCC1395	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3izZ2lEPTB;M{SuO\|E5PiEQvF2=	MlLKV2FPT0WU
8305C	NFzTR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnz2TWM2OD1\|NT64OFE2KM7:TR?=	M3Pke3NCVkeHUh?=
KM12	M3fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXS3ZnpxUUN3ME2zOk44PTR5IN88US=>	Mnm5V2FPT0WU
SW1116	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIC5VJhKSzVyPUO3MlU6QTJizszN	NFnue2tUSU6JRWK=
SK-MEL-1	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnOeWx5UUN3ME2zPE4{Ozh7IN88US=>	NWXCfmt{W0GQR1XS
HCC2218	NYPVR\|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTN6Lk[1NVkh\|ryP	MYrTRW5ITVJ?
T84	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr0b4hKSzVyPUO4Mlc1ODlizszN	NUj6OXFnW0GQR1XS
ETK-1	NHPIcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TIdWlEPTB;M{muNFIzKM7:TR?=	NVjVR5MyW0GQR1XS
COLO-800	M2DyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX5N2lXUUN3ME2zPU4{QDZ6IN88US=>	NUL6WI5zW0GQR1XS
CAL-12T	M4\pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LjZ2lEPTB;M{muOVI5OSEQvF2=	M334[3NCVkeHUh?=
ACN	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3zTWM2OD12MD60PVEyKM7:TR?=	NFLCd4xUSU6JRWK=
SJSA-1	M2fnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXNfoRFUUN3ME20NU4yPTl4IN88US=>	NIHVUnpUSU6JRWK=
PSN1	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HKT2lEPTB;NEGuNVc1QSEQvF2=	Mn7iV2FPT0WU
D-566MG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTRzLkKwPFYh\|ryP	M4rjeHNCVkeHUh?=
EGI-1	M1ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWC3NYpzUUN3ME20Nk41OjhizszN	NFnKXHpUSU6JRWK=
A204	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzCb\|g{UUN3ME20Nk43Ozh6IN88US=>	MUXTRW5ITVJ?
Saos-2	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTR{LkizOlkh\|ryP	Mle0V2FPT0WU
SNU-C2B	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LNT2lEPTB;NEOuOlg4QCEQvF2=	MnnDV2FPT0WU
HLE	NXH4bmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTR2LkC4OVYh\|ryP	MU\TRW5ITVJ?
SW1463	NYjY[ItRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;OdWlEPTB;NESuPVk4OSEQvF2=	M1;HNHNCVkeHUh?=
DSH1	M3PFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTR3LkCwN\|Mh\|ryP	NULKcI1OW0GQR1XS
MCF7	NWjaPIQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;neHdKSzVyPUS1MlUxPTFizszN	MkOxV2FPT0WU
K5	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\jTWM2OD12NT65OFA2KM7:TR?=	M1jjN3NCVkeHUh?=
NCI-H358	M3TafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTR5LkKxOUDPxE1?	MXPTRW5ITVJ?
NCI-H2030	NUPk[3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rn[WlEPTB;NEeuNlM4PCEQvF2=	NIH5OYxUSU6JRWK=
SW948	NYfHTo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PqZ2lEPTB;NEeuOFY1KM7:TR?=	MWfTRW5ITVJ?
BALL-1	M2[5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M32wOGlEPTB;NEeuOlE3QCEQvF2=	MWDTRW5ITVJ?
TE-9	M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\FUY17UUN3ME20O{46PThzIN88US=>	NGXIN2dUSU6JRWK=
SK-N-FI	M3;GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjNTWM2OD12OD6wN\|U5KM7:TR?=	MkXRV2FPT0WU
KALS-1	M1;jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPVd4dKSzVyPUS4MlEzQDlizszN	Mm\MV2FPT0WU
HO-1-N-1	NVq4PZlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHyTY9{UUN3ME20PE44PDR3IN88US=>	M{O4SnNCVkeHUh?=
NCI-H2452	NEPWeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPTdZhKSzVyPUS5MlEyPTJizszN	M2iyfnNCVkeHUh?=
OC-314	M1zXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTR7Lk[4N\|Qh\|ryP	MnG1V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.T790M\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Malignant Solid Neoplasm\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT00887757	Completed	Drug: ABT-263\|Drug: gemcitabine	Solid Tumors	AbbVie\|Genentech Inc.	September 2009	Phase 1
NCT00888108	Completed	Drug: ABT-263\|Drug: Docetaxel	Solid Tumor	Abbott\|Genentech Inc.	July 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)